Table 3 The probit analyses based on subgroups between biological equivalence dose and 12-month local control
From: Dose-effect relationship of linear accelerator based stereotactic radiotherapy for brain metastases
Parameter | Nominal BED10 (GyBED10) | Peripheral BED10 (GyBED10) | Central BED10 (GyBED10) | Average BED10 (GyBED10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | s (p) | ED90 (95% CI) | P | |
Country | ||||||||||||
Japan | 6 (256) | 89.2 (-, -) | 0.127 | 6 (256) | 76.4 (66.4, 138.6) | 0.020 | 5 (243) | 107.1(86.4,668.3) | 0.040 | 5 (243) | 91.6 (77.0, 183.5) | 0.016 |
Italy | 4 (391) | 53.7 (-, -) | 0.089 | 4 (391) | 53.7 (-, -) | 0.089 | 4 (391) | 62.23(56.1,64.1) | 0.003* | 4 (391) | 57.4 (-, -) | 0.066 |
Treatment era | ||||||||||||
Before 2010 | 13 (777) | 96.7 (-, -) | 0.054 | 13 (777) | 90.3 (-, -) | 0.054 | 11 (619) | 99.0 (84.1, 265.7) | 0.027 | 11 (619) | 85.1 (72.6, 156.7) | 0.013 |
After 2005 | 11 (737) | 71.4 (-, -) | 0.289 | 11 (737) | 94.0 (-, -) | 0.643 | 10 (724) | -28.3 (-, -) | 0.726 | 10 (724) | -218.5 (-, -) | 0.931 |
Proportion of male patients | ||||||||||||
≤ 50% | 10 (709) | 80.0 (-, -) | 0.062 | 10 (709) | 80.0 (-, -) | 0.062 | 8 (551) | 102.9 (82.3, 947.3) | 0.042 | 8 (551) | 83.1 (69. 3, 340.9) | 0.034 |
> 50% | 11 (564) | -704.1 (-, -) | 0.966 | 11 (564) | 108.2 (-, -) | 0.618 | 10 (629) | 25.1 (-, -) | 0.555 | 10 (629) | -168.6 (-, -) | 0.914 |
Median age | ||||||||||||
≥ 62 | 8 (569) | -1220.7 (-, -) | 0.974 | 8 (569) | 171.4 (-, -) | 0.764 | 7 (556) | 125.6 (-, -) | 0.425 | 7 (556) | 117.1 (-, -) | 0.551 |
< 62 | 11 (675) | 57.8 (49.8, 70.2) | 0.004 | 11 (675) | 57.7 (46.6, 79.1) | 0.017 | 10 (655) | 80.0 (-, -) | 0.089 | 10 (655) | 68.1 (-, -) | 0.072 |
Median tumour diameter ** | ||||||||||||
< 20 mm | 7 (610) | 157.1 (-, -) | 0.621 | 7 (610) | 120.1 (-, -) | 0.447 | 5 (459) | 92.7 (81.0, 201.8) | 0.026 | 5 (459) | 80.4 (69.1, 5208.3) | 0.049 |
≥ 20 mm | 9 (645) | 60.0 (-, -) | 0.214 | 9 (645) | 174.9 (-, -) | 0.929 | 8 (625) | 50.2 (-, -) | 0.159 | 8 (625) | 47.1 (-, -) | 0.209 |
PTV margin | ||||||||||||
≤ 2 mm | 12 (1153) | 211.9 (-, -) | 0.749 | 12 (1153) | 781.7 (-, -) | 0.948 | 10 (1002) | 98.2 (83.7, 951.9) | 0.044 | 10 (1002) | 84.9 (-, -) | 0.078 |
> 2 mm | 6 (237) | -29.5 (-, -) | 0.850 | 6 (237) | -619.9 (-, -) | 0.985 | 5 (217) | 77.4 (-6.7,104.2) | 0.034* | 5 (217) | 70.7 (-, -) | 0.089 |
Fractions | ||||||||||||
1 | 13 (1015) | 76.4 (66.6, 125.7) | 0.005 | 13 (1015) | 76.4 (66.6, 125.7) | 0.005 | 11 (864) | 98.5 (87.8, 141.0) | 0.003 | 11 (864) | 82.0 (73.8, 109.0) | 0.001 |
2–5 | 9 (467) | 40.9 (-, -) | 0.398 | 9 (467) | 39.3 (-, -) | 0.475 | 8 (447) | 65.2 (-, -) | 0.199 | 8 (447) | 59.6 (-, -) | 0.199 |
Treatment technology | ||||||||||||
CSC | 5 (366) | 58.1 (-, -) | 0.075 | 5 (366) | 58.1 (-, -) | 0.075 | 5 (366) | 87.7 (-, -) | 0.124 | 5 (366) | 73.2 (-, -) | 0.085 |
MLC | 9 (761) | 63.4 (-, -) | 0.119 | 9 (761) | 69.6 (-, -) | 0.374 | 9 (761) | 210.6 (-, -) | 0.841 | 9 (761) | 106.9 (-, -) | 0.655 |
Noncoplanar | 9 (885) | 412.5 (-, -) | 0.843 | 9 (885) | 559.0 (-, -) | 0.914 | 8 (747) | 122.5 (-, -) | 0.281 | 8 (747) | 108.5 (-, -) | 0.344 |
CNS | 2 | 3 | 6 | 5 | ||||||||